Characterization of an Akt kinase inhibitor with potent pharmacodynamic and antitumor activity

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Akt kinases 1, 2, and 3 are crucial for cell survival and frequently overactive in human tumors.
• Constitutive activation of Akt signaling pathways contributes to cancer development and progression.

Purpose of the Study:

• To evaluate GSK690693, a novel pan-Akt kinase inhibitor, as a potential anticancer therapeutic.
• To assess the in vitro and in vivo efficacy of GSK690693 in preclinical cancer models.

Main Methods:

• GSK690693 was tested for its inhibitory activity against Akt isoforms and downstream substrates.
• In vitro proliferation and apoptosis assays were performed on various cancer cell lines.
• In vivo studies involved xenograft models of human breast, ovarian, and prostate cancers in immune-compromised mice.

Main Results:

• GSK690693 demonstrated potent, dose-dependent inhibition of Akt phosphorylation and its downstream targets (GSK3 beta, PRAS40, Forkhead).
• The inhibitor reduced proliferation and induced apoptosis in a subset of tumor cells.
• Significant antitumor activity was observed in multiple human tumor xenograft models, with sustained inhibition of phosphorylated Akt substrates in vivo.
• Transient increases in blood glucose levels were noted, consistent with Akt's role in insulin signaling.

Conclusions:

• GSK690693 exhibits promising anticancer properties by effectively inhibiting the Akt pathway.
• The compound's ability to suppress tumor growth and induce apoptosis in preclinical models warrants further clinical investigation.
• GSK690693 represents a potential novel therapeutic strategy for cancers driven by Akt pathway activation.